These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23576166)

  • 1. [Metastatic malignant melanoma. Successfull treatment with ipilimumab].
    Jansen T; Bruch-Gerharz D; Reifenberger J; Schulte KW
    Hautarzt; 2013 Apr; 64(4):228, 230-1. PubMed ID: 23576166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.
    Lipson EJ; Drake CG
    Clin Cancer Res; 2011 Nov; 17(22):6958-62. PubMed ID: 21900389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profile of ipilimumab and its role in the treatment of metastatic melanoma.
    Patel SP; Woodman SE
    Drug Des Devel Ther; 2011; 5():489-95. PubMed ID: 22267918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
    Schadendorf D; Hodi FS; Robert C; Weber JS; Margolin K; Hamid O; Patt D; Chen TT; Berman DM; Wolchok JD
    J Clin Oncol; 2015 Jun; 33(17):1889-94. PubMed ID: 25667295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upcoming strategies for the treatment of metastatic melanoma.
    Spagnolo F; Queirolo P
    Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids.
    Chasset F; Pages C; Biard L; Roux J; Sidina I; Madelaine I; Basset-Seguin N; Viguier M; Madjlessi-EzrA N; Schneider P; Bagot M; Resche-Rigon M; Lebbe C
    Eur J Dermatol; 2015; 25(1):36-44. PubMed ID: 25500362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.
    Lipson EJ; Bodell MA; Kraus ES; Sharfman WH
    J Clin Oncol; 2014 Jul; 32(19):e69-71. PubMed ID: 24493726
    [No Abstract]   [Full Text] [Related]  

  • 9. Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.
    Gibney GT; Atkins MB
    J Clin Oncol; 2015 Jun; 33(17):1873-7. PubMed ID: 25964248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
    Di Giacomo AM; Ascierto PA; Pilla L; Santinami M; Ferrucci PF; Giannarelli D; Marasco A; Rivoltini L; Simeone E; Nicoletti SV; Fonsatti E; Annesi D; Queirolo P; Testori A; Ridolfi R; Parmiani G; Maio M
    Lancet Oncol; 2012 Sep; 13(9):879-86. PubMed ID: 22894884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
    Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
    Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report.
    Woźniak S; Mackiewicz-Wysocka M; Krokowicz Ł; Kwinta Ł; Mackiewicz J
    Oncol Res Treat; 2015; 38(3):105-8. PubMed ID: 25792081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy.
    Harmankaya K; Erasim C; Koelblinger C; Ibrahim R; Hoos A; Pehamberger H; Binder M
    Med Oncol; 2011 Dec; 28(4):1140-4. PubMed ID: 20593249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
    Zimmer L; Eigentler TK; Kiecker F; Simon J; Utikal J; Mohr P; Berking C; Kämpgen E; Dippel E; Stadler R; Hauschild A; Fluck M; Terheyden P; Rompel R; Loquai C; Assi Z; Garbe C; Schadendorf D
    J Transl Med; 2015 Nov; 13():351. PubMed ID: 26541511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.
    Wolchok JD; Weber JS; Maio M; Neyns B; Harmankaya K; Chin K; Cykowski L; de Pril V; Humphrey R; Lebbé C
    Ann Oncol; 2013 Aug; 24(8):2174-80. PubMed ID: 23666915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.
    Mathew M; Tam M; Ott PA; Pavlick AC; Rush SC; Donahue BR; Golfinos JG; Parker EC; Huang PP; Narayana A
    Melanoma Res; 2013 Jun; 23(3):191-5. PubMed ID: 23462208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vemurafenib and ipilimumab: new agents for metastatic melanoma.
    Banaszynski M; Kolesar JM
    Am J Health Syst Pharm; 2013 Jul; 70(14):1205-10. PubMed ID: 23820456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant ipilimumab in stage III melanoma: New landscape, new questions.
    Eggermont AM
    Eur J Cancer; 2016 Dec; 69():39-42. PubMed ID: 27816830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ipilimumab: a novel treatment for metastatic melanoma.
    Culver ME; Gatesman ML; Mancl EE; Lowe DK
    Ann Pharmacother; 2011 Apr; 45(4):510-9. PubMed ID: 21505108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients.
    Konstantinou MP; Dutriaux C; Gaudy-Marqueste C; Mortier L; Bedane C; Girard C; Thellier S; Jouary T; Grob JJ; Richard MA; Templier C; Sakji L; Guillot B; Paul C; Meyer N
    Acta Derm Venereol; 2014 Jan; 94(1):45-9. PubMed ID: 23824275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.